NOT-HL-20-737 - Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases
PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)
he purpose of this Notice is to indicate NINR's participation in NOT-HL-20-737 "Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases."
NINR will accept R01 applications on palliative care research in heart, lung, blood, and sleep (HLBS) diseases. NINR supports research across adult and pediatric populations with a focus on the clinical and biobehavioral aspects of acute or chronic advanced heart, vascular, lung and blood diseases, conditions and sleep. NINR has a principal focus on research in symptom management and incorporation of palliative, supportive, and end-of-life care interventions, strategies and outcomes for HLBS patients and family-caregivers across the lifespan, care settings and diverse populations. The Institute has a long-standing interest in end-of-life and palliative care clinical studies of advanced HLBS conditions and disease and supports research that will significantly increase an understanding of the palliative management and interventions for these populations.
This NOSI encourages research applications within the NINR mission area of end-of-life and palliative care research. Applicants are encouraged to contact the Scientific/Research contact listed below to ensure that proposed aims are consistent with the mission of NINR. NINR interests include, but are not limited to:
- Studies examining and using HLBS clinical characteristics/triggers for initiating palliative or hospice care and the criteria for palliative or hospice care in all settings, including critical care.
- Studies focusing on grief and bereavement, caregiver burden, and caregiver health associated with HLBS palliative care.
- Studies of the social/ethical issues surrounding HLBS patients at high risk of dying including recurrent hospitalizations, deactivation/withdrawal of ventricular assistive devices (VAD) or use of life-sustaining treatments. Studies may include interventions, implementation strategies, or clinical tools to increase early engagement in the HLBS advance care planning process, patient-family-provider communication, and shared goals of care conversations (e.g., treatment preferences, goals, and values).
- Studies addressing the efficacy/effectiveness and the mechanism(s) of HLBS-related strategies for management of symptoms such as pain and sleep-related related daily function and quality of life (e.g., biomarkers, non-pharmacologic approaches, behavioral health). Studies addressing concomitant comorbid conditions are desirable.
- Studies exploring the causes and impacts of HLBS transitions between primary and acute/critical care and the effects of this fragmentation on clinical practice and patient- and family-centered health outcomes.
- Studies developing and implementing novel data sources and technologies (e.g., digital health, bioinformatics, AI and information technology) for outcome driven HLBS palliative care.
- Studies addressing the impact of the integration social determinants of care in improving access to and quality of HLBS palliative care. Addressing barriers to palliative care in NIH-designated health disparity populations including racial and ethnic minorities, sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations with serious, advanced HLBS are encouraged.
Applicants are encouraged to engage the resources and expertise of existing palliative care networks such as the Palliative Care Research Cooperative Group when appropriate.
NIH clinical trial considerations and limitations apply to all R01 applications with a clinical trial component. NINR will only accept responsive applications submitted to PA-20-183 and PA-20-185
- PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
All other aspects of the NOSI remain the same.